Author

Gwen Levy

Observed names: G Levy, G. Levy, Levy, G.

Institution: AbbVie (United States)

Observed institution: AbbVie (United States)

OpenAlex ID: A5000253629

A Phase II Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis

2019 · Roy M. Fleischmann, Henning Bliddal, et al. · Arthritis & Rheumatology · 224

Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis

2018 · Margreet Kloppenburg, Charles Peterfy, et al. · Annals of the Rheumatic Diseases · 174

DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis

2022 · S Vermeire, S Danese, et al. · Journal of Crohn s and Colitis · 12

OP0168 A phase 2a, placebo-controlled, randomized study of ABT-981, an anti-interleukin-1ALPHA and -1BETA dual variable domain immunoglobulin, to treat erosive hand osteoarthritis (EHOA)

2017 · M Kloppenburg, C Peterfy, et al. · Annals of the Rheumatic Diseases · 12

SAT0575 Safety and efficacy of lutikizumab (ABT-981), an anti–interleukin-1 alpha/beta dual variable domain (DVD) immunoglobulin, in subjects with knee osteoarthritis: results from the randomised, double-blind, placebo-controlled, parallel-group phase 2 trial

2018 · R. Fleischmann, H. Bliddal, et al. · Annals of the Rheumatic Diseases · 9

P518 Safety of upadacitinib in ulcerative colitis: Long-term data from the phase 3 open-label extension study (U-ACTIVATE)

2023 · R Panaccione, G Lichtenstein, et al. · Journal of Crohn s and Colitis · 5

P658 Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect Comparison

2023 · W Reinisch, J Tran, et al. · Journal of Crohn s and Colitis · 3

P546 Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison

2023 · W Reinisch, R Panaccione, et al. · Journal of Crohn s and Colitis · 3

P179 Comparative benefit-risk profile of induction and maintenance therapy with upadacitinib versus placebo in patients with moderately to severely active ulcerative colitis

2023 · I Blumenstein, S Xuan, et al. · Journal of Crohn s and Colitis

A Phase 2A, Placebo-Controlled, Randomized Study of ABT-981, an Anti-Interleukin-1Alpha and-1Beta Dual Variable Domain Immunoglobulin, to Treat Erosive Hand Osteoarthritis

2017 · M. Kloppenburg, C. Peterfy, et al. · Data Archiving and Networked Services (DANS)

Works count: 11

Citation count: 447

H-index: 6

I10-index: 4